All results
5 results for randomized multicenter double blind placebo controlled parallel group phase 3 study
-
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…
- Ages
- 18 Years - N/A
- Sexes
- All
-
IMPALA-2
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…
- Ages
- 18 Years - N/A
- Sexes
- All
-
BLOCK-SAH
BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of…
- Ages
- 18 Years - 85 Years
- Sexes
- All
-
GCAptAIN
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…
- Ages
- 50 Years - N/A
- Sexes
- All
-
REPLENISH
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52…
- Ages
- 50 Years - N/A
- Sexes
- All